Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients

Liu, Chin‐San; Lii, Chong‐Kuei; Chang, Li‐Ling; Kuo, Chen‐Ling; Cheng, Wen-Ling; Su, Shih‐Li; Tsai, Chia-Wen; Chen, Haw‐Wen

doi:10.1016/j.nutres.2010.01.007

Cited by 20 publications

(18 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the absolute levels of both 7-K and 25-OH were reduced in brain, while 7-K absolute levels were increased in serum without change in 25-OH in dogs receiving atorvastatin. Further, after correction for total cholesterol [65,78], we observed consistent effects.…”

Section: Discussionsupporting

confidence: 59%

See 1 more Smart Citation

Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: A novel mechanism of action

Barone

Cenini

Domenico

et al. 2011

Pharmacological Research

View full text Add to dashboard Cite

Alzheimer disease (AD) is an age-related neurodegenerative disorder characterized by progressive memory loss, inability to perform the activities of daily living and personality changes. Unfortunately, drugs effective for this disease are limited to acetylcholinesterase inhibitors that do not impact disease pathogenesis. Statins, which belong to the class of cholesterol-reducing drugs, were proposed as novel agents useful in AD therapy, but the mechanism underlying their neuroprotective effect is still unknown. In this study, we show that atorvastatin may have antioxidant effects, in aged beagles, that represent a natural higher mammalian model of AD. Atorvastatin (80 mg/day for 14.5 months) significantly reduced lipoperoxidation, protein oxidation and nitration, and increased GSH levels in parietal cortex of aged beagles. This effect was specific for brain because it was not paralleled by a concomitant reduction in all these parameters in serum. In addition, atorvastatin slightly reduced the formation of cholesterol oxidation products in cortex but increased the 7-ketocholesterol/total cholesterol ratio in serum. We also found that increased oxidative damage in the parietal cortex was associated with poorer learning (visual discrimination task). Thus, a novel pharmacological effect of atorvastatin mediated by reducing oxidative damage may be one mechanism underlying benefits of this drug in AD.

show abstract

Section: Discussionsupporting

confidence: 59%

“…Interestingly, many pathways modified by statins could have direct effects on AD pathogenesis and Aβ associated neuropathology. Among these effects is the antioxidant effect exerted by atorvastatin [65–69]. …”

Section: Discussionmentioning

confidence: 99%

Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: A novel mechanism of action

Barone

Cenini

Domenico

et al. 2011

Pharmacological Research

View full text Add to dashboard Cite

show abstract

“…One study conducted in mice demonstrated that low and high doses of RYR (monacolin K, respectively, 15 and 75 mg/kg body weight) induced a dramatic decline in CoQ10 levels in the heart and liver (Yang, 2005). Clinical trials conducted with lovastatin or atorvastatin at respectively 60 and 10 mg daily showed a decrease of plasma CoQ10 levels (Palomaki, 1998;Liu, 2010). In our study, a downward trend was observed in the NCLS group for CoQ10 levels (p = 0.0682).…”

Section: Discussionsupporting

confidence: 50%

A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial

Barrat¹,

Zaïr²,

Ogier³

et al. 2013

International Journal of Food Sciences and Nutrition

View full text Add to dashboard Cite

show abstract

“…Approximately 60% of CoQ10 is transported via the LDL molecule; therefore, large reductions in LDL may significantly affect the concentrations of free CoQ10 in the blood 39 . This can be corrected by using the CoQ10/LDL ratio.…”

Section: Discussionmentioning

confidence: 99%

“…This can be corrected by using the CoQ10/LDL ratio. Studies are conflicting regarding the effect of statins on CoQ10/LDL ratio, though some have demonstrated an increase in the ratio 3, 6–7,39 .…”

Section: Discussionmentioning

confidence: 99%

Effect of rosuvastatin on plasma coenzyme Q10 in HIV-infected individuals on antiretroviral therapy

Morrison

Longenecker

Mittelsteadt

et al. 2016

HIV Clinical Trials

View full text Add to dashboard Cite

BACKGROUND Coenzyme Q10 (CoQ10) deficiency has been associated with statin-induced myopathy, and supplementation with CoQ10 may reduce inflammation markers. The effects of statins on CoQ10 and its anti-inflammatory properties have not been investigated in HIV-positive patients. OBJECTIVE The objectives of this study were to examine the effect of rosuvastatin on CoQ10 and CoQ10/LDL ratio over 24 weeks SATURN-HIV trial, explore the associations between CoQ10 levels and markers of vascular disease, inflammation, and immune activation, and assess whether changes in CoQ10 affected the anti-inflammatory effects of statin therapy or were associated with myalgia symptoms. METHODS This was a secondary analysis of the SATURN-HIV trial, a 96-week randomized clinical trial of 10mg daily rosuvastatin vs. placebo in HIV-infected patients on antiretroviral therapy. We assessed the statin treatment effect on CoQ10 levels and CoQ10/LDL ratios and whether changes in these markers were related to myalgias. Relationships between CoQ10, subclinical vascular disease, and biomarkers of inflammation and immune activation were explored using Spearman correlations and multivariable regression models. RESULTS Overall, 147 patients were included. Median age was 46 years; 78% were male, 68% African American. At baseline, CoQ10 levels and CoQ10/LDL ratio were modestly correlated with markers of HIV disease, immune activation, and carotid distensibility. After 24 weeks of statin therapy, CoQ10 levels decreased (p=0.002 for between group difference) and CoQ10/LDL ratio increased (p=0.036). In the statin treatment arm, we did not find evidence of a relationship between changes in CoQ10 or CoQ10/LDL ration and changes in markers of inflammation or immune activation. There was a borderline statistically significant association between changes in CoQ10 and myalgia symptoms [OR 4.0 per 0.1mg/L decrease in CoQ10, p=0.07]. CONCLUSION Twenty-four weeks of 10mg daily rosuvastatin decreases CoQ10 concentration and increases CoQ10/LDL ratio in HIV-infected patients on antiretroviral therapy.

show abstract

Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients

Cited by 20 publications

References 43 publications

Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: A novel mechanism of action

Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: A novel mechanism of action

A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial

Effect of rosuvastatin on plasma coenzyme Q10 in HIV-infected individuals on antiretroviral therapy

Contact Info

Product

Resources

About